Data from other types of cancers with high incidence, such as prostate; breast; colorectal; urinary/bladder and skin cancers (melanoma); hematological cancers, such as non-Hodgkin lymphoma; and brain cancers, such as glioblastoma, are needed for anti-TIGIT antibodies. Here, TIGIT is linked to hematopoietic and lymphoid cell neoplasm.